팔리페리돈 장기지속형 주사제 중단에 영향을 미치는 인자
Factors affecting Discontinuation of Paliperidone Long Acting Injection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives：Paliperidone palmitate long-acting injection(PP) is an effective and broadly well tolerated treatment in practice. The aim of this study was to determine factors relating to discontinuation with treatment with PP, we analyzed the time course and causes of PP discontinuation that occurred in 12 months period in a clinical setting. Methods：Retrospective database of 81 patients with schizophrenia were reviewed for analyzing the duration of PP and the reasons for discontinuation(from June 2011 to November 2016), with the motives for discontinuation coded. The causes for termination were analyzed. Results：Overall, 58% patients discontinued PP beyond 12 months from initiation. The common reasons for discontinuation were follow-up loss(42.5%), no effect(19.1%), side effect(19.1%). extrapyramidal symptom accounted for 44.4% of all side effect inducing discontinuation. Pain, somnolence accounted for 22.2% of side effect, respectively. Inpatient initiation, switched from risperidone, risperidone long-acting injection(LAI), compliance before injection, hospitalization during treatment course, GAF score at last LAI, CGI-S at last LAI were associated with discontinuation on univariate analysis. However, only hospitalization during treatment course was independently associated with discontinuation on multivariate analysis. Conclusion：Hospitalization after PP was associated with 12-month PP discontinuation. Prospective researches using more objective tools are needed to clarify the reasons for PP discontinuation.
Abstract
Objectives：Paliperidone palmitate long-acting injection(PP) is an effective and broadly well tolerated treatment in practice. The aim of this study was to determine factors relating to discontinuation with treatment with PP, we analyzed the time course and causes of PP discontinuation that occurred in 12 months period in a clinical setting. Methods：Retrospective database of 81 patients with schizophrenia were reviewed for analyzing the duration of PP and the reasons for discontinuation(from June 2011 to November 2016), with the motives for discontinuation coded. The causes for termination were analyzed. Results：Overall, 58% patients discontinued PP beyond 12 months from initiation. The common reasons for discontinuation were follow-up loss(42.5%), no effect(19.1%), side effect(19.1%). extrapyramidal symptom accounted for 44.4% of all side effect inducing discontinuation. Pain, somnolence accounted for 22.2% of side effect, respectively. Inpatient initiation, switched from risperidone, risperidone long-acting injection(LAI), compliance before injection, hospitalization during treatment course, GAF score at last LAI, CGI-S at last LAI were associated with discontinuation on univariate analysis. However, only hospitalization during treatment course was independently associated with discontinuation on multivariate analysis. Conclusion：Hospitalization after PP was associated with 12-month PP discontinuation. Prospective researches using more objective tools are needed to clarify the reasons for PP discontinuation.
참고문헌 (29)
- Gelder M, "New Oxford Textbook of Psychiatry" (2000), Oxford University Press
- Schennach R, "Predictors of relapse in the year after hospital discharge among patients with schizophrenia", Psychiatr Serv, 63, pp.87~90 (2012)
- Chen EY, "A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients", Schizophr Res, 77, pp.99~104 (2005)
- Pigott TA, "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia:a placebo-controlled 26-week study", J Clin Psychiatry, 64, pp.1048~1056 (2003)
- Fatemi SH, "The neurodevelopmental hypothesis of schizophrenia, revisited", Schizophr Bull, 35, pp.528~548 (2009)
- Almond S, "Relapse in schizophrenia: cost, clinical outcomes and quality of life", Br J Psychiatry, 184, pp.346~351 (2004)
- Adams CE, "Systematic meta-review of depot antipsychotic drugs for people with schizophrenia", Br J Psychiatry, 179, pp.290~299 (2001)
- Hough D, "Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebocontrolled study", Schizophr Res, 116, pp.107~117 (2010)
- Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
- Kishimoto T, "Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia:a meta-analysis of randomized trials", Schizophr Bull, 40, pp.192~213 (2014)
- Leucht C, "Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and metaanalysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
- Gaebel W, "Towards the improvement of compliance:the significance of psycho-education and new antipsychotic drugs", Int Clin Psychopharmacol, 12, pp.S37~S42 (1997)
- Zhu B, "Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia", Psychiatr Serv, 59, pp.315~317 (2008)
- Llorca PM, "Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness", BMC Psychiatry, 13, pp.340~ (2013)
- Kaplan G, "Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia", Patient Prefer Adherence, 7, pp.1171~1180 (2013)
- Leucht S, "Evidencebased pharmacotherapy of schizophrenia", Int J Neuropsychopharmacol, 14, pp.269~284 (2011)
- Carter, NJ, "Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia", Drugs, 72, pp.1137~1160 (2012)
- 김하린, "팔리페리돈 장기지속형주사제의 약물 순응도와 치료 효과", 신경정신의학, 54(1), pp.69~75 (2015), 대한신경정신의학회[DOI]
- Whale R, "Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12 month naturalistic cohort study", J Clin Psychopharmacol, 35, pp.591~595 (2015)
- Taylor DM, "Paliperidone palmitate: factors predicting continuation with treatment at 2 years", Eur Neuropsychopharmacol, 26, pp.2011~2017 (2016)
- Velligan Di, "The expert consensus guideline series:adherence problems in patients with serious and persistent mental illness", J Clin Psychiatry, 70, pp.1~46 (2009)
- Attard A, "Paliperidone palmitate long-acting injection-prospective year-long follow-up use in clinical practice", Acta Psychiatr Scand, 130, pp.46~51 (2014)
- Taylor DM, "Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome", Int J Neuropsychopharmacol, 9, pp.685~694 (2006)
- Olfson M, "Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone", Schizophr Bull, 33, pp.1379~1387 (2007)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Lambert M, "Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis", J Clin Psychopharmacol, 30, pp.565~572 (2010)
- Moritz S, "Nonadherence to antipsychotics:the role of positive attitudes towards positive symptoms", Eur Neuropsychopharmacol, 24, pp.1745~1752 (2014)
- Karow A, "Association of Subjective Well-being, Symptoms, and Side Effects With Compliance After 12 Months of Treatment in Schizophrenia", J Clin Psychiatry, 68, pp.75~80 (2007)
- Novick D, "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia", Psychiatry Res, 176, pp.109~113 (2010)